Look back at pharma news in week to April 13

15 April 2018

By Barbara Obstoj-Cardwell, Editor

Mergers and acquisitions were very much in the news last week. First, there was Novartis announced takeover of US gene therapy firm AveXis for around $8.7 billion, and then came Alexion Pharmaceuticals, with a bid of around $855 million for Sweden’s Wilson Therapeutics and its rare disease candidate WTX101. On the research front, the good news was that Merck & Co announced significant success for its blockbuster drug Keytruda in lung cancer, and AbbVie released positive Phase III trial data on its upadacitinib. Not so good was that NewLink is reviewing its IDO program following the disappointment of Incyte’s epacadostat trial, and that vTv Therapeutics’ Alzheimer’s disease candidate azeliragon has failed in a Phase III study.

Novartis acquisition a vote of confidence for gene therapy

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK